Iovance Biotherapeutics, Inc. (IOVA) stock price plummeted 5.08% in the intraday trading session on Monday. The decline was likely driven by analysts lowering their price targets on the company's stock.
Truist Securities lowered its price target on Iovance Biotherapeutics from $25 to $15, while maintaining a Buy rating on the stock. This followed the company's fourth-quarter results, which prompted analysts to reevaluate their expectations.
Additionally, Chardan Capital Markets reduced its price target on Iovance Biotherapeutics from $34 to $30, although it maintained a Buy rating as well. According to analysts polled by FactSet, the company currently has an average rating of Buy and a mean price target of $20.62.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.